in-stent restenosis

in-stent restenosis

Interventional cardiology Scar-induced reclosure of a previously stenosed coronary artery, a complication seen in ±20% of Pts undergoing stent placement for CAD. See Coronary artery disease, Stent. Cf Late stent thrombosis.
References in periodicals archive ?
Suppression of neointimal hyperplasia, the underlying cause of in-stent restenosis, by 17 beta-estradiol released from the stent surface, represents a novel approach for drug eluting stents, and is the basis for the ETHOS I and ETHOS II clinical studies.
In-stent hyperplasia was 83% lower, in-stent restenosis was 91% lower, and in-segment restenosis was 75% lower in those with sirolimus-eluting stents than in those with plain metal stents.
Imaging of devices such as stents under MRI by using nanomagnetic particle coatings to generate resonant circuits that allow visualization of in-stent restenosis and clotting.
At 6-month follow-up, there was no evidence of late luminal loss or in-stent restenosis in any patient who received the eluting stent.
Suppression of neointimal hyperplasia, the underlying cause of in-stent restenosis, by 17(beta)-estradiol released from the stent surface, represents a novel approach for drug eluting stents and is the basis for the ETHOS I and ETHOS II clinical studies.
Among the more than 25 key CYPHER(R) Stent presentations at the international medical conference are results from the robust, international e-CYPHER(SM) registry, which tracks use of the device in more than 15,000 patients; and studies that evaluate the CYPHER(R) Stent's performance in complex cases, including diabetic patients, elderly populations, and patients with in-stent restenosis.
The treatment substantially reduced in-stent restenosis and was associated with a 6.
In the past few years LKEB has developed several useful tools for quantitative analysis: the segmentation of vessel trees and vessel segments after the positioning of seed points, the quantitative analysis (diameter, area and stenosis measurements) of vessel segments, and quantitative analysis of in-stent restenosis in peripheral vessels (which was specifically developed for an in-stent restenosis study at Bio-Imaging).
30 /PRNewswire/ -- Results of a multi-center, prospective study involving two leading drug-eluting stents were presented today, with data indicating that patients with long areas of vessel blockage (> 24mm) treated with the Cypher Sirolimus-eluting Stent had less in-stent late loss (tissue growth inside the stent) and less in-stent restenosis (reblockage) than patients treated with the Taxus Express 2 Stent or a bare metal stent.
Data from four new international clinical studies suggest the potential for the CYPHER(R) Sirolimus-eluting Coronary Stent to treat higher-risk and more challenging blockages in coronary arteries, including small vessel blockages, chronic total occlusions, in-stent restenosis and multi-vessel disease.
BRUSSELS, Belgium, April 8 /PRNewswire/ -- Cordis Corporation, a Johnson & Johnson company, reported today it received CE mark approval to market its CYPHER SELECT(tm) Sirolimus-eluting Coronary Stent in all Member States of the European Union (EU), European Economic Area (EEA) and Switzerland for the treatment of in-stent restenosis (repeat blockage inside of a coronary stent) in patients with coronary artery disease.

Full browser ?